|
Compound instance
|
|
0
|
14
|
September 11, 2024
|
|
LMFI(log2 median fluorescence intensity values)
|
|
0
|
28
|
July 21, 2024
|
|
PRISM Batch effect
|
|
0
|
24
|
July 19, 2024
|
|
User drug sensitivity (PRISM Repurposing Primary screen)
|
|
3
|
311
|
April 24, 2024
|
|
9-ING-41 repurposing hub data
|
|
1
|
129
|
April 5, 2024
|
|
How to find a specific analysis
|
|
1
|
146
|
March 12, 2024
|
|
Data issue with PRISM drug repurposing dataset
|
|
2
|
167
|
March 8, 2024
|
|
Interpretation of Drug sensitivity AUC and Logfold change value
|
|
8
|
5869
|
March 8, 2024
|
|
Data Removed? Navitoclax single agent data
|
|
5
|
131
|
February 12, 2024
|
|
Prism drug repurposing score
|
|
1
|
434
|
September 12, 2023
|
|
Viability at a given dosage from AUC
|
|
2
|
747
|
August 17, 2023
|
|
Difference between Mifepristone Compounds
|
|
0
|
189
|
July 28, 2023
|
|
How to inverse the AUC value for drug sensitivity screens
|
|
0
|
409
|
January 5, 2023
|
|
About compounds
|
|
0
|
270
|
October 31, 2022
|
|
PRISM data and identified cell lines
|
|
0
|
390
|
September 20, 2022
|
|
Antibody Drug Conjugates
|
|
0
|
294
|
August 29, 2022
|
|
Drug sensitivity (PRISM Repurposing Primary Screen) 19Q4
|
|
2
|
2505
|
July 18, 2022
|
|
NA targets in the PRISM 19Q4 dataset
|
|
2
|
509
|
May 24, 2022
|
|
Are IC50 values downloadable from DepMap log or z-transformed or normalized in some way?
|
|
1
|
736
|
May 3, 2022
|
|
Availability of cell lines from DepMap
|
|
3
|
492
|
April 12, 2022
|
|
Is it possible to separate drug sensitivity into two categories: Sensitive / Resistance?
|
|
1
|
511
|
April 7, 2022
|
|
EGFR inhibitor data of lung cancer cells
|
|
1
|
792
|
January 26, 2022
|
|
How to interpret AUC value
|
|
7
|
2396
|
January 11, 2022
|
|
Estimation of uncertainty around the dose-response curve
|
|
1
|
496
|
January 11, 2022
|
|
X and Y axis meanings
|
|
3
|
900
|
January 7, 2022
|
|
Drug screen data (PRISM)
|
|
1
|
563
|
January 3, 2022
|
|
Cancer versus non-cancer dependencies
|
|
4
|
3769
|
December 3, 2021
|
|
Compound annotations/translating BRD ID's
|
|
1
|
639
|
October 21, 2021
|
|
Interpreting NA Values in 19Q4 PRISM Primary screen
|
|
1
|
433
|
October 8, 2021
|
|
Identify putative drugs and pertubagens that selectively sensitize specific cancer cell lines for translational cancer research
|
|
2
|
680
|
July 17, 2021
|
